RecruitingAngioedema
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
use of lanadelumab in patients with acquired angioedema
Sponsor: Bernstein Clinical Research Center
You may qualify if…
- ✓ A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
- ✓ historical attack rate of \>= on attack per month prior to starting tranexamic acid (TAA)
You may not qualify if…
- ✕ History of anaphylaxis or hypersensitivity to biologics
- ✕ History of major systemic disease not well controlled in opinion of the PI
- ✕ Women who are pregnant or breast feeding
- ✕ Concurrent participation in other clinical trials
- ✕ HAE Type 1 or 2 and normal complement HAE
Where it's recruiting
Ohio
Cincinnati
Source: ClinicalTrials.gov · NCT06818474 · last updated 2025-02-25